The study provides an in-depth analysis of the market with current trends and future estimations to elucidate the imminent investment pockets.
Portland, OR -- (SBWIRE) -- 09/18/2017 -- Norfloxacin is a synthetic broad spectrum antibiotic, which acts against most gram-negative and gram-positive bacteria. This antibiotic is mainly used to treat urinary tract infections by inhibiting bacterial cell division.
Access to the full summary: https://www.alliedmarketresearch.com/norfloxacin-market
The major factors that contribute to the growth of the norfloxacin market include the high prevalence of urinary tract infections (UTI), chronic diseases, and rise in geriatric population contributing to a large patient pool. Moreover, large number of clinical trials and innovative R&D approaches to develop advanced antibiotics drive the market growth. However, development of drug-resistant strains and side effects associated with the use of antibiotic restrain the market growth. The development of prospect molecules and novel combination therapies by R&D processes, which are used to treat antibiotic-resistant microbial infections further provides various opportunities for market growth.
The key players operating in this market include Janssen Pharmaceuticals, Merck KGaA, Eli. Lilly & Co., Bristol-Myers Squibb Company, GlaxoSmithKline plc, AbZ-Pharma GmbH, F. Hoffmann-La Roche AG, Shandong Xinhua Pharmaceutical, Kyorin Pharmaceutical Co., Ltd., and Lancer Health Care Pvt. Ltd.
Norfloxacin Market Key Segments:
By Brand Names
- Uncomplicated Urinary Tract Infections
- Complicated Urinary Tract Infections
- Uncomplicated Urethral and Cervical Gonorrhea
Get sample PDF: https://www.alliedmarketresearch.com/request-toc-and-sample/4050
- Rest of Europe
- Rest of Asia-Pacific
- Saudi Arabia
- South Africa
- Rest of LAMEA